Target
Ephrin type-B receptor 2
Ligand
BDBM50538438
Substrate
n/a
Meas. Tech.
ChEMBL_1972847 (CHEMBL4605665)
IC50
93±n/a nM
Citation
 Kaiser, TMDentmon, ZWDalloul, CESharma, SKLiotta, DC Accelerated Discovery of Novel Ponatinib Analogs with Improved Properties for the Treatment of Parkinson's Disease. ACS Med Chem Lett 11:491-496 (2020) [PubMed]  Article 
Target
Name:
Ephrin type-B receptor 2
Synonyms:
DRT | Developmentally-regulated Eph-related tyrosine kinase | ELK-related tyrosine kinase | EPH tyrosine kinase 3 | EPH-like kinase 5 | EPHB2 | EPHB2_HUMAN | EPHT3 | EPTH3 | ERK | Ephrin receptor | HEK5 | TYRO5
Type:
PROTEIN
Mol. Mass.:
117491.44
Organism:
Homo sapiens (Human)
Description:
ChEMBL_1476221
Residue:
1055
Sequence:
MALRRLGAALLLLPLLAAVEETLMDSTTATAELGWMVHPPSGWEEVSGYDENMNTIRTYQVCNVFESSQNNWLRTKFIRRRGAHRIHVEMKFSVRDCSSIPSVPGSCKETFNLYYYEADFDSATKTFPNWMENPWVKVDTIAADESFSQVDLGGRVMKINTEVRSFGPVSRSGFYLAFQDYGGCMSLIAVRVFYRKCPRIIQNGAIFQETLSGAESTSLVAARGSCIANAEEVDVPIKLYCNGDGEWLVPIGRCMCKAGFEAVENGTVCRGCPSGTFKANQGDEACTHCPINSRTTSEGATNCVCRNGYYRADLDPLDMPCTTIPSAPQAVISSVNETSLMLEWTPPRDSGGREDLVYNIICKSCGSGRGACTRCGDNVQYAPRQLGLTEPRIYISDLLAHTQYTFEIQAVNGVTDQSPFSPQFASVNITTNQAAPSAVSIMHQVSRTVDSITLSWSQPDQPNGVILDYELQYYEKELSEYNATAIKSPTNTVTVQGLKAGAIYVFQVRARTVAGYGRYSGKMYFQTMTEAEYQTSIQEKLPLIIGSSAAGLVFLIAVVVIAIVCNRRGFERADSEYTDKLQHYTSGHMTPGMKIYIDPFTYEDPNEAVREFAKEIDISCVKIEQVIGAGEFGEVCSGHLKLPGKREIFVAIKTLKSGYTEKQRRDFLSEASIMGQFDHPNVIHLEGVVTKSTPVMIITEFMENGSLDSFLRQNDGQFTVIQLVGMLRGIAAGMKYLADMNYVHRDLAARNILVNSNLVCKVSDFGLSRFLEDDTSDPTYTSALGGKIPIRWTAPEAIQYRKFTSASDVWSYGIVMWEVMSYGERPYWDMTNQDVINAIEQDYRLPPPMDCPSALHQLMLDCWQKDRNHRPKFGQIVNTLDKMIRNPNSLKAMAPLSSGINLPLLDRTIPDYTSFNTVDEWLEAIKMGQYKESFANAGFTSFDVVSQMMMEDILRVGVTLAGHQKKILNSIQVMRAQMNQIQSVEGQPLARRPRATGRTKRCQPRDVTKKTCNSNDGKKKGMGKKKTDPGRGREIQGIFFKEDSHKESNDCSCGG
  
Inhibitor
Name:
BDBM50538438
Synonyms:
CHEMBL4640297
Type:
Small organic molecule
Emp. Form.:
C29H26ClN7O
Mol. Mass.:
524.016
SMILES:
Cc1ccc(cc1C#Cc1cnc2cccnn12)C(=O)Nc1ccc(CN2CCC3C=NNC3C2)c(Cl)c1 |c:33|
Structure:
Search PDB for entries with ligand similarity: